Skip to main content

Table 2 Logistic regression of predictors for MRA initiation by cohort in the CKD population

From: Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study

Independent variables

CKD

DKD

CKD + HF

DKD + HF

Odds ratio

Confidence interval

P value

Odds ratio

Confidence interval

P value

Odds ratio

Confidence interval

P value

Odds ratio

Confidence interval

P value

Lower limit

Upper limit

Lower limit

Upper limit

Lower limit

Upper limit

Lower limit

Upper limit

Age, years (vs 18–34 years)

 35–44

1.93

1.43

2.61

< 0.0001

1.15

0.72

1.82

0.5666

0.82

0.50

1.34

0.4255

1.10

0.47

2.53

0.83

 45–54

1.48

1.11

1.96

0.0075

1.01

0.66

1.55

0.9672

0.98

0.64

1.51

0.9423

1.31

0.60

2.85

0.50

 55–64

1.31

0.99

1.73

0.0593

0.90

0.59

1.37

0.6131

0.70

0.46

1.06

0.0897

1.14

0.53

2.48

0.73

 65+

0.95

0.71

1.27

0.7419

0.63

0.41

0.98

0.0381

0.40

0.27

0.61

< 0.0001

0.80

0.37

1.74

0.58

Sex (vs male)

 Female

1.43

1.28

1.59

< 0.0001

1.04

0.93

1.16

0.4554

0.77

0.66

0.89

0.0004

0.83

0.73

0.93

0.002

Prescribing physician specialty at inclusion (vs general/family practice)

 Internal Medicine

1.04

0.86

1.26

0.695

1.25

1.03

1.52

0.0266

1.03

0.77

1.39

0.8268

1.30

1.02

1.66

0.03

 Cardiology

1.28

0.93

1.75

0.126

1.11

0.78

1.59

0.5677

1.36

0.97

1.92

0.0789

1.79

1.34

2.40

< 0.0001

 Nephrology

1.45

1.22

1.73

< 0.0001

1.76

1.47

2.10

< 0.0001

1.27

0.95

1.70

0.1068

1.11

0.88

1.41

0.38

 Hospital

1.69

1.38

2.07

< 0.0001

1.49

1.21

1.85

0.0002

2.09

1.61

2.73

< 0.0001

1.68

1.34

2.11

< 0.0001

Other/unknown

1.34

1.12

1.601

0.0017

1.24

1.02

1.51

0.0288

1.50

1.15

1.95

0.0027

1.30

1.03

1.63

0.02

Previous medication use (yes vs no)

 ARBs

1.75

1.55

1.97

< 0.0001

1.62

1.44

1.82

< 0.0001

1.40

1.19

1.65

< 0.0001

1.34

1.18

1.52

< 0.0001

 ACE inhibitors

1.24

1.10

1.39

0.0003

1.37

1.22

1.54

< 0.0001

1.33

1.16

1.54

< 0.0001

1.34

1.19

1.51

< 0.0001

 Renin inhibitors

2.11

1.44

3.10

0.0001

1.66

1.21

2.27

0.0016

1.28

0.65

2.52

0.476

1.25

0.83

1.890

0.28

 Vasodilators

2.20

1.92

2.53

< 0.0001

1.64

1.45

1.86

< 0.0001

1.25

1.06

1.46

0.0066

0.97

0.85

1.09

0.59

Comorbidities

 LVH

1.26

0.97

1.65

0.0884

1.71

1.39

2.09

< 0.0001

1.71

1.46

2.000

< 0.0001

1.28

1.11

1.46

0.0005

 Anemia

1.07

0.94

1.21

0.2916

0.84

0.74

0.95

0.0063

0.72

0.62

0.84

< 0.0001

0.70

0.62

0.79

< 0.0001

 Edema

2.14

1.85

2.47

< 0.0001

2.09

1.83

2.38

< 0.0001

1.48

1.26

1.73

< 0.0001

1.47

1.30

1.66

< 0.0001

 Proteinuria

1.18

1.00

1.41

0.0571

1.31

1.13

1.51

0.0004

0.82

0.59

1.15

0.2475

0.98

0.80

1.20

0.85

 Hyperkalemia

0.96

0.71

1.30

0.8046

0.55

0.42

0.73

< 0.0001

0.49

0.34

0.70

0.0001

0.57

0.45

0.71

< 0.0001

 Sensitivity testing: c-statistic

0.67

0.66

0.68

0.63

  1. ACE acetylcholinesterase, ARB angiotensin II receptor blocker, CKD chronic kidney disease, DKD diabetic kidney disease, HF heart failure, LVH left ventricular hypertrophy, MRA mineralocorticoid receptor antagonist
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us